JAK2 Inhibitors Developed by S*BIO Target Inroads to North American and European Markets

摘要

S*BIO Pte Ltd, a Singapore-based company, has entered into a development collaboration, and option and license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize S*BIO's novel JAK2 inhibitors, SB 1518 and SB 1578. Under the terms of the agreement, S*BIO is eligible to receive up to US550 million dollar in combined equity purchase, option and license fees, and development and sales milestone payments. This includes an upfront payment and upfront equity purchase totaling US 25 million dollar. S*Bio is also eligible to receive up to double-digit royalties on any sales.